Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Expenditures (2021 - 2023)

Aligos Therapeutics filings provide 3 years of Capital Expenditures readings, the most recent being $7000.0 for Q1 2023.

  • On a quarterly basis, Capital Expenditures fell 98.64% to $7000.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $435000.0, a 60.45% decrease, with the full-year FY2024 number at $130000.0, up 584.21% from a year prior.
  • Capital Expenditures hit $7000.0 in Q1 2023 for Aligos Therapeutics, down from $91000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $515000.0 in Q1 2022 to a low of $3000.0 in Q3 2022.
  • Median Capital Expenditures over the past 3 years was $152000.0 (2021), compared with a mean of $204666.7.
  • Biggest five-year swings in Capital Expenditures: soared 119.74% in 2022 and later crashed 98.64% in 2023.
  • Aligos Therapeutics' Capital Expenditures stood at $336000.0 in 2021, then tumbled by 72.92% to $91000.0 in 2022, then crashed by 92.31% to $7000.0 in 2023.
  • The last three reported values for Capital Expenditures were $7000.0 (Q1 2023), $91000.0 (Q4 2022), and $3000.0 (Q3 2022) per Business Quant data.